Literature DB >> 28844375

High mortality rate associated with KPC-producing Enterobacter cloacae in a Brazilian hospital.

Kesia Esther da Silva1, Tháigor Rezek Varella1, Graciela Mendonça Dos Santos Bet2, Cecília Godoy Carvalhaes3, Maisa Estopa Correa1, Nathalie Gaebler Vasconcelos2, Julio Croda4, Ana Cristina Gales3, Simone Simionatto5.   

Abstract

We describe a clonal dissemination of KPC-producing Enterobacter cloacae in a Brazilian hospital. Patients diagnosed with theses isolates showed high mortality rate (41.8%) and were associated with previous use of antibiotics and urinary catheterization. Therefore, infection control measures and use of stricter antibiotic policies are required to control the spread of these organisms.
Copyright © 2018 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic resistance; Enterobacteriaceae; β-lactamases

Mesh：

Substances：

Year:  2017        PMID： 28844375     DOI： 10.1016/j.ajic.2017.07.011

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN： 0196-6553            Impact factor:   2.918


  4 in total

1.  Carbapenem-Resistant Enterobacter cloacae Causing Nosocomial Infections in Southwestern China: Molecular Epidemiology, Risk Factors, and Predictors of Mortality.

Authors:  Xiaolang Tian; Changwu Huang; Xiaoli Ye; Hongyan Jiang; Rufang Zhang; Xiaofang Hu; Dongshuang Xu
Journal:  Infect Drug Resist       Date:  2020-01-10       Impact factor: 4.003

2.  Molecular characterization of NDM-1-producing carbapenem-resistant E. cloacae complex from a tertiary hospital in Chongqing, China.

Authors:  Kewang Hu; Jisheng Zhang; Jingbo Zou; Lingyi Zeng; Jie Li; Jianmin Wang; Wenzhang Long; Xiaoli Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-08-08       Impact factor: 6.073

3.  The in vitro activity of polymyxin B and tigecycline alone and combination with other antibiotics against carbapenem-resistant Enterobacter cloacae complex isolates, including high-risk clones.

Authors:  Yongxin Zhao; Chunjiang Li; Jisheng Zhang; Yanjun Fu; Kewang Hu; Shanshan Su; Yong Wang; Huiling Li; Xiaoli Zhang
Journal:  Ann Transl Med       Date:  2019-12

Review 4.  Harnessing the Natural Toxic Metabolites in COVID-19.

Authors:  Ali Bahrami; Mohammad Taheri; Mohammad Reza Arabestani; Meysam Soleimani; Mojdeh Mohammadi; Fatemeh Golabchi; Maryam Banitorfi; Seyed Mostafa Hosseini; Sodabe Khodabandehlou; Fatemeh Nouri
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-07       Impact factor: 2.629
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.